Keep Reading Published on: July 20, 2020 Frank&LlenCare When you first glance at Frank and Ellenora "Llen" Ryan, the word " fighter " likely isn't the top quality that pops into mind
During my first week, I lost 3 pounds, and Ive been averaging 2 to 3 pounds per week since
Vanessa Mack (Dean) Monitors Your Progress After the First Semaglutide GLP-1 Injection in Scottsdale, AZ Dr
Highlights Understanding weight as a whole health ecosystem, not a willpower issue Ashleys journey and how generational experiences shape weight health The main weight-health hormones and how they influence the body GLP-1 medications: who they help, who they may harm, and what practitioners must screen for Understanding these medications system-wide effects as a practitioner Microdosing vs low-dose GLP-1 and why individualized dosing is critical A multifactorial framework for assessing weight-health hormone function Supporting long COVID, MCAS, endometriosis, autoimmune issues, and chronic pain How GLP-1 agonists may influence gut, immune, and receptor-level functioning Peptides, protein diversity, and their impact on pain and metabolic health Differences between short-acting and long-acting GLP-1 medications How to approach weaning off GLP-1s Examining internalized bias, ableism, and beauty standards in weight-related decisions Connect with Ashley Koff, RD The Better Nutrition Program GLP-1 Assessment Ashley Koffs Book | Your Best Shot: The Personalized System for Optimal Weight HealthGLP-1 Shot or Not Ashley Koff on Instagram @ashleykoffapproved About Ashley Koff, RD Ashley Koff, RD, is the founder of The Better Nutrition Program (BNP), the Nutrition Course Director for UC Irvines Susan Samueli Integrative Health Institutes Integrative and Functional Medicine Fellowship, and a faculty member at the Integrative and Functional Nutrition Academy (IFNA), where she teaches An Integrative and Functional Nutrition Approach to Obesity and Weight Management. She is also the author of the upcoming book, Your Best Shot (Harper One, January 6, 2026)
Con gli inibitori forti del CYP3A4 (claritromicina, ketoconazolo, itraconazolo, ritonavir) la dose massima di orforglipron limitata a 9 mg al giorno
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
